Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.

Xiaoyan LiAotian ShenYiran ZhaoJun-Feng Xia

Published in: Schizophrenia bulletin (2023)

Our findings with genetic support were more likely to be to succeed in clinical trials. In addition, our study prioritizes approved drug targets for the development of new therapies and provides critical drug reuse opportunities for psychiatric disorders.

Keyphrases

clinical trial
genome wide
adverse drug
randomized controlled trial
gene expression
study protocol
open label